Jounce faces hostile takeover bid from minority stakeholder
Cancer biotech Jounce Therapeutics has gotten a hostile takeover bid from Concentra Biosciences, a San Diego company backed by Tang Capital Partners.
Tang Capital is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.